The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold

Key Clinical Message There is no effective treatment that reduces both the severity and duration of a common cold episode. SJP − 002 (naproxen and fexofenadine) reduced symptom severity by two‐third, and the duration of the common cold episode approximately by half. Abstract The common cold is one o...

Full description

Bibliographic Details
Main Authors: Emina Išerić, Thomas A. Dahl, Andrew Scholey, Jacqueline M. Iversen, Joris C. Verster
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:Clinical Case Reports
Subjects:
Online Access:https://doi.org/10.1002/ccr3.7682
_version_ 1797772051451215872
author Emina Išerić
Thomas A. Dahl
Andrew Scholey
Jacqueline M. Iversen
Joris C. Verster
author_facet Emina Išerić
Thomas A. Dahl
Andrew Scholey
Jacqueline M. Iversen
Joris C. Verster
author_sort Emina Išerić
collection DOAJ
description Key Clinical Message There is no effective treatment that reduces both the severity and duration of a common cold episode. SJP − 002 (naproxen and fexofenadine) reduced symptom severity by two‐third, and the duration of the common cold episode approximately by half. Abstract The common cold is one of the most frequently experienced immune‐related complaints. At present, available treatments have limited efficacy in inhibiting symptoms associated with upper respiratory tract infection, nor do they significantly shorten the duration of common cold episodes. Four case reports are presented of individuals with a common cold. Three of them self‐administered the combination of naproxen and fexofenadine (SJP − 002). Results of one individual were compared to her spouse, who did not take SJP − 002 to treat common cold, while two other individuals took SJP − 002 and compared symptom severity with another common cold episode they experienced previously without taking SJP − 002. SJP − 002 reduced the severity of symptoms associated with upper respiratory tract infection by two‐third and reduced the duration of the common cold episode approximately by half. In conclusion, SJP − 002 reduced the severity and duration of common cold episodes. These findings warrant further investigation of SJP − 002 in double‐blind, placebo‐controlled clinical trials.
first_indexed 2024-03-12T21:45:24Z
format Article
id doaj.art-8f080281f022427fb73784f700d7ee6f
institution Directory Open Access Journal
issn 2050-0904
language English
last_indexed 2024-03-12T21:45:24Z
publishDate 2023-07-01
publisher Wiley
record_format Article
series Clinical Case Reports
spelling doaj.art-8f080281f022427fb73784f700d7ee6f2023-07-26T12:00:46ZengWileyClinical Case Reports2050-09042023-07-01117n/an/a10.1002/ccr3.7682The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common coldEmina Išerić0Thomas A. Dahl1Andrew Scholey2Jacqueline M. Iversen3Joris C. Verster4Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS) Utrecht University Utrecht The NetherlandsSen‐Jam Pharmaceutical Huntington New York USANutrition Dietetics and Food, School of Clinical Sciences Monash University Melbourne Victoria AustraliaSen‐Jam Pharmaceutical Huntington New York USADivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS) Utrecht University Utrecht The NetherlandsKey Clinical Message There is no effective treatment that reduces both the severity and duration of a common cold episode. SJP − 002 (naproxen and fexofenadine) reduced symptom severity by two‐third, and the duration of the common cold episode approximately by half. Abstract The common cold is one of the most frequently experienced immune‐related complaints. At present, available treatments have limited efficacy in inhibiting symptoms associated with upper respiratory tract infection, nor do they significantly shorten the duration of common cold episodes. Four case reports are presented of individuals with a common cold. Three of them self‐administered the combination of naproxen and fexofenadine (SJP − 002). Results of one individual were compared to her spouse, who did not take SJP − 002 to treat common cold, while two other individuals took SJP − 002 and compared symptom severity with another common cold episode they experienced previously without taking SJP − 002. SJP − 002 reduced the severity of symptoms associated with upper respiratory tract infection by two‐third and reduced the duration of the common cold episode approximately by half. In conclusion, SJP − 002 reduced the severity and duration of common cold episodes. These findings warrant further investigation of SJP − 002 in double‐blind, placebo‐controlled clinical trials.https://doi.org/10.1002/ccr3.7682common coldfexofenadinenaproxenrhinovirusSJP − 002treatment
spellingShingle Emina Išerić
Thomas A. Dahl
Andrew Scholey
Jacqueline M. Iversen
Joris C. Verster
The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold
Clinical Case Reports
common cold
fexofenadine
naproxen
rhinovirus
SJP − 002
treatment
title The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold
title_full The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold
title_fullStr The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold
title_full_unstemmed The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold
title_short The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold
title_sort efficacy of a combination of naproxen and fexofenadine sjp 002 to inhibit the symptoms that are associated with viral upper respiratory tract infection four case reports of individuals with common cold
topic common cold
fexofenadine
naproxen
rhinovirus
SJP − 002
treatment
url https://doi.org/10.1002/ccr3.7682
work_keys_str_mv AT eminaiseric theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT thomasadahl theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT andrewscholey theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT jacquelinemiversen theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT joriscverster theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT eminaiseric efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT thomasadahl efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT andrewscholey efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT jacquelinemiversen efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT joriscverster efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold